Company Overview of RayBiotech, Inc.
RayBiotech, Inc. develops and commercializes technologies and tools for genomics and proteomics research applications. Its products include cytokine antibody, quantitative antibody, apoptosis, phosphorylation antibody, label-based antibody, and protein arrays; enzyme immunoassay, ELISA, cell-based ELISA, and phosphorylation ELISA kits; and protein products, peptides and peptide synthesis tools, and tissue microarrays. The company also offers antibody, membrane, glass-slide, label, quantibody, and phosphorylation array testing services; and custom antibody production, custom recombinant protein, ELISA testing, peptide synthesis, assay development, discovery, consulting, and array printing. It...
3607 Parkway Lane
Norcross, GA 30092
Founded in 2001
Key Executives for RayBiotech, Inc.
Director of Marketing and Business Development
Vice President of Commercial Development
Compensation as of Fiscal Year 2015.
RayBiotech, Inc. Key Developments
RayBiotech, Inc. Partners with XCellCure, LLC to Develop and Market Cardiovascular Disease Diagnostic Kit
Apr 28 14
RayBiotech, Inc. announced that it has partnered with XCellCure, LLC to develop a proprietary cardiovascular disease diagnostic kit. Under the terms of the partnership the companies will co-market and co-distribute the kits worldwide, first for research use with the long-term goal of its implementation in clinical diagnostics and prognostics applications. The financial terms were not disclosed.
RayBiotech, Inc. Executes Master Services and Supply Agreement with California Stem Cell, Inc
Mar 13 14
RayBiotech, Inc. announced that it has executed a master services and supply agreement with California Stem Cell, Inc. CSC utilizes high-purity stem cells in a number of therapeutics applications including for the treatment of melanoma, ovarian cancer and a variety of neurologic disorders. Under the terms of this agreement, California Stem Cell will receive preferred pricing and other proprietary guarantees on both services and products from RayBiotech. The financial terms were not disclosed.
RayBiotech, Inc. Enters into Partnership with the Genomics Core Facility of Fox Chase Cancer Center
Dec 17 13
RayBiotech, Inc. announced that it has entered into a partnership with the Genomics Core Facility of Fox Chase Cancer Center. Under the terms of the partnership, RayBiotech will provide comprehensive GLP-compliant biomarker discovery and validation services to Fox Chase Cancer Center and its researchers. In addition, RayBiotech will offer GMP-compliant and ISO 13485: 2003-certified diagnostic discovery products to the Genomics Core Facility and Fox Chase Cancer Center researchers campus-wide. These services and products correspond to RayBiotech's broad range of antibody array and ELISA product lines and will be provided under preferred pricing conditions specifically formulated for Fox Chase Cancer Center.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|